188 related articles for article (PubMed ID: 16525503)
1. An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis.
Boeddrich A; Gaumer S; Haacke A; Tzvetkov N; Albrecht M; Evert BO; Müller EC; Lurz R; Breuer P; Schugardt N; Plassmann S; Xu K; Warrick JM; Suopanki J; Wüllner U; Frank R; Hartl UF; Bonini NM; Wanker EE
EMBO J; 2006 Apr; 25(7):1547-58. PubMed ID: 16525503
[TBL] [Abstract][Full Text] [Related]
2. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates.
Zhong X; Pittman RN
Hum Mol Genet; 2006 Aug; 15(16):2409-20. PubMed ID: 16822850
[TBL] [Abstract][Full Text] [Related]
3. Valosin-containing protein (VCP/p97) is an activator of wild-type ataxin-3.
Laço MN; Cortes L; Travis SM; Paulson HL; Rego AC
PLoS One; 2012; 7(9):e43563. PubMed ID: 22970133
[TBL] [Abstract][Full Text] [Related]
4. Structural and mechanistic insights into the arginine/lysine-rich peptide motifs that interact with P97/VCP.
Liu S; Fu QS; Zhao J; Hu HY
Biochim Biophys Acta; 2013 Dec; 1834(12):2672-8. PubMed ID: 24100225
[TBL] [Abstract][Full Text] [Related]
5. A functional deficiency of TERA/VCP/p97 contributes to impaired DNA repair in multiple polyglutamine diseases.
Fujita K; Nakamura Y; Oka T; Ito H; Tamura T; Tagawa K; Sasabe T; Katsuta A; Motoki K; Shiwaku H; Sone M; Yoshida C; Katsuno M; Eishi Y; Murata M; Taylor JP; Wanker EE; Kono K; Tashiro S; Sobue G; La Spada AR; Okazawa H
Nat Commun; 2013; 4():1816. PubMed ID: 23652004
[TBL] [Abstract][Full Text] [Related]
6. ATX-3, CDC-48 and UBXN-5: a new trimolecular complex in Caenorhabditis elegans.
Rodrigues AJ; Neves-Carvalho A; Ferro A; Rokka A; Corthals G; Logarinho E; Maciel P
Biochem Biophys Res Commun; 2009 Sep; 386(4):575-81. PubMed ID: 19545544
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and aggregation of the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila melanogaster.
Ristic G; Sutton JR; Libohova K; Todi SV
Neurobiol Dis; 2018 Aug; 116():78-92. PubMed ID: 29704548
[TBL] [Abstract][Full Text] [Related]
8. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
9. H1152 promotes the degradation of polyglutamine-expanded ataxin-3 or ataxin-7 independently of its ROCK-inhibiting effect and ameliorates mutant ataxin-3-induced neurodegeneration in the SCA3 transgenic mouse.
Wang HL; Hu SH; Chou AH; Wang SS; Weng YH; Yeh TH
Neuropharmacology; 2013 Jul; 70():1-11. PubMed ID: 23347954
[TBL] [Abstract][Full Text] [Related]
10. Nucleocytoplasmic shuttling activity of ataxin-3.
Macedo-Ribeiro S; Cortes L; Maciel P; Carvalho AL
PLoS One; 2009 Jun; 4(6):e5834. PubMed ID: 19503814
[TBL] [Abstract][Full Text] [Related]
11. Regulation of ER-associated degradation via p97/VCP-interacting motif.
Ballar P; Fang S
Biochem Soc Trans; 2008 Oct; 36(Pt 5):818-22. PubMed ID: 18793143
[TBL] [Abstract][Full Text] [Related]
12. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3.
Haacke A; Broadley SA; Boteva R; Tzvetkov N; Hartl FU; Breuer P
Hum Mol Genet; 2006 Feb; 15(4):555-68. PubMed ID: 16407371
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates.
Donaldson KM; Li W; Ching KA; Batalov S; Tsai CC; Joazeiro CA
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8892-7. PubMed ID: 12857950
[TBL] [Abstract][Full Text] [Related]
15. A key lysine residue in the AXH domain of ataxin-1 is essential for its ubiquitylation.
Kang AR; Park SH; Lee S; Choi DY; Kim KP; Song HK; Hong S; Kang S
Biochim Biophys Acta; 2015 May; 1854(5):356-64. PubMed ID: 25641559
[TBL] [Abstract][Full Text] [Related]
16. The slow Wallerian degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it within the nucleus.
Laser H; Conforti L; Morreale G; Mack TG; Heyer M; Haley JE; Wishart TM; Beirowski B; Walker SA; Haase G; Celik A; Adalbert R; Wagner D; Grumme D; Ribchester RR; Plomann M; Coleman MP
Mol Biol Cell; 2006 Mar; 17(3):1075-84. PubMed ID: 16371511
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of an ataxin-1-interacting protein: A1Up, a ubiquitin-like nuclear protein.
Davidson JD; Riley B; Burright EN; Duvick LA; Zoghbi HY; Orr HT
Hum Mol Genet; 2000 Sep; 9(15):2305-12. PubMed ID: 11001934
[TBL] [Abstract][Full Text] [Related]
18. p97/valosin-containing protein (VCP) is highly modulated by phosphorylation and acetylation.
Mori-Konya C; Kato N; Maeda R; Yasuda K; Higashimae N; Noguchi M; Koike M; Kimura Y; Ohizumi H; Hori S; Kakizuka A
Genes Cells; 2009 Apr; 14(4):483-97. PubMed ID: 19335618
[TBL] [Abstract][Full Text] [Related]
19. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
20. Progress in pathogenesis studies of spinocerebellar ataxia type 1.
Cummings CJ; Orr HT; Zoghbi HY
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1079-81. PubMed ID: 10434309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
